Updated

Electra Therapeutics is seeking a valuation of roughly $977.6 million as it moves ahead with a U.S. initial public offering, according to newly disclosed filings. The biotech listing adds to a steady stream of health-care sector IPOs this year as companies look to capitalize on relatively receptive public markets. Details of the offering size and pricing terms were not fully disclosed, but the targeted valuation places Electra among the larger clinical-stage biotech listings of the year. Investors will be watching the deal as a gauge of appetite for biotech IPOs heading into the fourth quarter.